Synovial sarcoma X breakpoint protein (SSX) (SSX)

Synovial sarcoma X breakpoint (SSX) proteins are a family of cancer-testis antigens (CTAs) that primarily function as transcriptional repressors and chromatin modulators (UniProt, Q16385). Under normal physiological conditions, their expression is restricted to the germ cells of the testis, but they are aberrantly expressed in various malignancies, including synovial sarcoma, melanoma, and multiple myeloma (PubMed, PMID: 15150595). In synovial sarcoma, a characteristic chromosomal translocation t(X;18)(p11;q11) results in the SS18-SSX fusion protein, which acts as a potent oncogenic driver by hijacking and dysregulating the BAF (SWI/SNF) chromatin-remodeling complex (Nature, PMID: 29618823). Because of their highly restricted expression in normal tissues and high prevalence in tumors, SSX proteins—particularly SSX2—are prime targets for cancer immunotherapy (Journal for ImmunoTherapy of Cancer, PMID: 32661118). Current therapeutic strategies focus on T-cell receptor (TCR) engineered T-cell therapies, such as GSK3845097, and cancer vaccines designed to elicit a robust cytotoxic T-lymphocyte response against SSX-expressing tumor cells (ClinicalTrials.gov, NCT04052334). These therapies often require patients to be positive for specific HLA types, such as HLA-A*02:01, to ensure proper antigen presentation (PubMed, PMID: 25103445).

Other names

SSX familyCancer-testis antigenSynovial sarcoma, X breakpointSSX1SSX2SSX3SSX4SSX5SSX7SSX8SSX9

T-cell receptor (TCR) engineered T-cell therapy and peptide-based vaccination designed to induce cytotoxic T-lymphocyte responses against SSX-expressing cells.